Cambridge Investment Research Advisors’s Co-Diagnostics CODX Stock Holding History

Cambridge Investment Research Advisors’s Portfolio CODX Stock Details CODX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,829	Closed	-$81K	–	3191
2023 Q1	$81K	Sell	1,829 -5	-0.3%	-$401	﹤0.01%	2989
2022 Q4	$139K	Sell	1,834 -333	-15%	-$31.2K	﹤0.01%	2852
2022 Q3	$209K	Buy	+2,167	New	+$303K	﹤0.01%	2665
2021 Q2	–	Sell	-348	Closed	-$99K	–	3102
2021 Q1	$99K	Buy	+348	New	+$139K	﹤0.01%	2758
2020 Q3	–	Sell	-376	Closed	-$218K	–	2532
2020 Q2	$218K	Buy	+376	New	+$172K	﹤0.01%	2119

Other funds holding CODX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

KOC

Koss-Olinger Consulting Gainesville, Florida $1.19B AUM 15.91% 1-Year Est. Return

Cambridge Investment Research Advisors's CODX Position: Q2 2023 in Review

Cambridge Investment Research Advisors sold out of Co-Diagnostics (CODX) in Q2 2023, closing a stake of 1,829 shares — an estimated $81K sold.

Cambridge Investment Research Advisors first reported a position in CODX in Q2 2020 and held it in 5 quarters. The position peaked at $218K in Q2 2020. 43 funds tracked by Wall St. Rank hold CODX as of Q2 2023.

Cambridge Investment Research Advisors reported no remaining Co-Diagnostics position as of Q2 2023 after selling out during the quarter.
Cambridge Investment Research Advisors sold 1,829 Co-Diagnostics shares in Q2 2023, an estimated $81K.
Cambridge Investment Research Advisors first reported a position in Co-Diagnostics in Q2 2020 and held it in 5 quarters.
Cambridge Investment Research Advisors's Co-Diagnostics position peaked at $218K in Q2 2020.
43 funds tracked by Wall St. Rank held Co-Diagnostics as of Q2 2023.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2023, filed 13 Jul 2023.